J. Joshua Smith

Jul 2, 2024 | medscape.com | Benjamin L. Schlechter |J. Joshua Smith

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Benjamin L. Schlechter, MD: Hello. I'm Dr Benjamin Schlechter. Welcome to Medscape's InDiscussion series on colorectal cancer. Today we're discussing nonoperative management of rectal cancer with our guest, Dr Joshua Smith.

May 30, 2024 | nature.com | Andrew Waters |Justine C. Rutter |Shannon McCall |Mariaelena Pierobon |J. Joshua Smith |Channing J. Der

AbstractAcquired resistance remains a major challenge for therapies targeting oncogene activated pathways. KRAS is the most frequently mutated oncogene in human cancers, yet strategies targeting its downstream signaling kinases have failed to produce durable treatment responses.

Mar 14, 2024 | nature.com | Yoshinori Kagawa |J. Joshua Smith |Emmanouil Fokas |Jun Watanabe |Florian R. Greten |Hideaki Bando | +3 more

AbstractDespite therapeutic advancements, disease-free survival and overall survival of patients with locally advanced rectal cancer have not improved in most trials as a result of distant metastases. For treatment decision-making, both long-term oncologic outcomes and impact on quality-of-life indices should be considered (for example, bowel function).